Novo Nordisk launched the Wegovy weight-loss pill in the U.S., the first oral GLP-1 therapy approved by the FDA. The pill offers a convenient daily option for patients. Early traction has been strong, with over 3,000 retail prescriptions in the first days, driving a sharp increase in the company’s shares.

Novo Nordisk, a leader in chronic disease treatment, saw a surge in stock performance following the launch of Wegovy. The stock was up 19.26% this year after a challenging 2025. The FDA approval of Wegovy sparked a rally, with shares jumping as much as 7.3%.

Early data shows strong momentum for Wegovy, with thousands of prescriptions filled in the first week. This success positions Novo Nordisk to regain market share from competitors. Despite this, the sustainability of this growth remains uncertain, especially with upcoming competition from Eli Lilly.

Novo Nordisk reported solid financial results for the first nine months of 2025, with net sales reaching DKK 229.9 billion. Sales in the Diabetes and Obesity care segment rose by about 12%, driven by a significant increase in obesity care demand. The company has narrowed its full-year guidance amid intensified competition.

Analysts expect EPS to improve in fiscal 2025 but decline slightly in 2026. BMO Capital reiterated a “Market Perform” rating, while CICC Research initiated coverage with an “Outperform” rating. Wall Street’s consensus is a “Moderate Buy” with a stock price surpassing the average target.

Novo Nordisk’s stock is currently trading at a discount compared to the sector median. The company’s CEO expressed optimism for 2026, focusing on commercial execution, obesity, and diabetes. With positive ratings from analysts and a potential 15.36% upside based on the high target price, the stock shows promise for growth.

Read more at Yahoo Finance: The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?